-
Electronic (PDF)
-
Site License
-
Enterprisewide
Myocardial Ischemia - Pipeline Review, Q3 2011
Global Markets Direct, July 2011, Pages: 51
Myocardial Ischemia - Pipeline Review, Q3 2011
Summary
Global Markets Direct’s, 'Myocardial Ischemia - Pipeline Review, Q3 2011', provides an overview of the Myocardial Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myocardial Ischemia. 'Myocardial Ischemia - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Myocardial Ischemia.
- A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myocardial Ischemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Myocardial Ischemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia Overview
Therapeutics Development
An Overview of Pipeline Products for Myocardial Ischemia
Myocardial Ischemia Therapeutics under Development by Companies
Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Myocardial Ischemia Therapeutics - Products under Development by Companies
Myocardial Ischemia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Myocardial Ischemia Therapeutics Development
Cardium Therapeutics, Inc.
Advanced Cell Technology, Inc.
Cytori Therapeutics, Inc.
CardioVascular BioTherapeutics, Inc.
Ark Therapeutics Group plc
Merck KGaA
Viromed Co., Ltd.
Baxter Healthcare Corporation
Eribis Pharmaceuticals AB
Biopeutics co., Ltd.
Myocardial Ischemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
EG011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Generx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Papeilin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eprex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Evasin-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EP 94 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adipose Tissue-Derived Stem And Regenerative Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemangioblast Cell Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adult Autologous CD34+ Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MANF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone-Marrow Mononuclear Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myocardial Ischemia Therapeutics – Drug Profile Updates
Myocardial Ischemia - Featured News
Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program
Sep 03, 2008: Chrysalin (Rusalatide Acetate, TP508) Pre-Clinical Results Show Significant Beneficial Effect In Chronic Heart Disease
Apr 24, 2008: International Research Team Publishes Details Of TB4's Cardioprotective Effects In Ischemia-Reperfusion Study
Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Myocardial Ischemia, Q3 2011
Products under Development for Myocardial Ischemia – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Cardium Therapeutics, Inc., 2011
Advanced Cell Technology, Inc., 2011
Cytori Therapeutics, Inc., 2011
CardioVascular BioTherapeutics, Inc., 2011
Ark Therapeutics Group plc, 2011
Merck KGaA, 2011
Viromed Co., Ltd., 2011
Baxter Healthcare Corporation, 2011
Eribis Pharmaceuticals AB, 2011
Biopeutics co., Ltd., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Myocardial Ischemia Therapeutics – Drug Profile Updates
List of Figures
Number of Products under Development for Myocardial Ischemia, Q3 2011
Products under Development for Myocardial Ischemia – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
